Clinicopathological analysis of claudin 18.2 focusing on intratumoral heterogeneity and survival in patients with metastatic or unresectable gastric cancer
T-Y Kim, Y Kwak, SK Nam, D Han, D-Y Oh, S-A Im, HS Lee · 2024
Read Clinicopathological analysis of claudin 18.2 focusing on intratumoral heterogeneity and survival in patients with metastatic or unresectable gastric cancer by T-Y Kim, Y Kwak, SK Nam, D Han, D-Y Oh, S-A Im, HS Lee (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11648117.txt.
Description
Tae-Young Kim and co-authors profiled in 2024 a drug target called claudin 18.2 in four hundred patients with advanced stomach cancer, asking how common it is and how patchy within each tumor. Patchiness matters: a biopsy can miss the target entirely. They stained four cores per tumor and compared them with whole sections.
Over sixty percent of expressing tumors disagreed across their own cores, yet the four-core verdict matched whole sections almost always. About thirty-one percent of patients tested positive overall. Positivity clustered in virus-linked tumors and shunned the lower stomach and HER2-positive cases. Survival did not differ by the marker alone. But marker-positive tumors rich in a second immune marker lived longer and held more killer T cells. The authors say the map should guide new therapies.
Catalog record
| CREATOR | T-Y Kim, Y Kwak, SK Nam, D Han, D-Y Oh, S-A Im, HS Lee |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 37 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |